Characterization of the Blood–Brain Barrier Integrity and the Brain Transport of SN-38 in an Orthotopic Xenograft Rat Model of Diffuse Intrinsic Pontine Glioma
Authors:
- Catarina ChavesCCCatarina Chaves
- Xavier DeclèvesXDXavier Declèves
- Meryam TaghiMTMeryam Taghi
- Marie-Claude MenetMMMarie-Claude Menet
- Joelle LacombeJLJoelle Lacombe
- Pascale VarletPVPascale Varlet
- Nagore G. OlacireguiNONagore G. Olaciregui
- Angel M. CarcabosoACAngel M. Carcaboso
- Salvatore CisterninoSalvatore Cisternino
Open Access
- 27 April 2020
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (5) , 399
Abstract
The blood–brain barrier (BBB) hinders the brain delivery of many anticancer drugs. In pediatric patients, diffuse intrinsic pontine glioma (DIPG) represents the main cause of brain cancer mortality lacking effective drug therapy. Using sham and DIPG-bearing rats, we analyzed (1) the brain distribution of 3-kDa-Texas red-dextran (TRD) or [14C]-sucrose as measures of BBB integrity, and (2) the role of major ATP-binding cassette (ABC) transporters at the BBB on the efflux of the irinotecan metabolite [3H]-SN-38. The unaffected [14C]-sucrose or TRD distribution in the cerebrum, cerebellum, and brainstem regions in DIPG-bearing animals suggests an intact BBB. Targeted proteomics retrieved no change in P-glycoprotein (P-gp), BCRP, MRP1, and MRP4 levels in the analyzed regions of DIPG rats. In vitro, DIPG cells express BCRP but not P-gp, MRP1, or MRP4. Dual inhibition of P-gp/Bcrp, or Mrp showed a significant increase on SN-38 BBB transport: Cerebrum (8.3-fold and 3-fold, respectively), cerebellum (4.2-fold and 2.8-fold), and brainstem (2.6-fold and 2.2-fold). Elacridar increased [3H]-SN-38 brain delivery beyond a P-gp/Bcrp inhibitor effect alone, emphasizing the role of another unidentified transporter in BBB efflux of SN-38. These results confirm a well-preserved BBB in DIPG-bearing rats, along with functional ABC-transporter expression. The development of chemotherapeutic strategies to circumvent ABC-mediated BBB efflux are needed to improve anticancer drug delivery against DIPG.Keywords
Funding Information
- ERA-NET : CURE2DIPG (EURONANOMED2015)
This publication has 50 references indexed in Scilit:
- ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B–Driven Brainstem Glioma ModelMolecular Cancer Therapeutics, 2016
- Tumor location, but not H3.3K27M, significantly influences the blood–brain-barrier permeability in a genetic mouse model of pediatric high-grade gliomaJournal of Neuro-Oncology, 2015
- DIPG in Children – What Can We Learn from the Past?Frontiers in Oncology, 2015
- P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclibInvestigational New Drugs, 2015
- Convection enhanced delivery of carmustine to the murine brainstem: A feasibility studyJournal of Neuroscience Methods, 2014
- Novel therapeutic delivery approaches in development for pediatric gliomasCNS Oncology, 2013
- In Vitro Drug Response and Efflux Transporters Associated with Drug Resistance in Pediatric High Grade Glioma and Diffuse Intrinsic Pontine GliomaPLOS ONE, 2013
- Diffuse intrinsic pontine glioma—current status and future strategiesChild's Nervous System, 2011
- Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children's Oncology Group phase I studyNeuro-Oncology, 2008
- Advances Toward an Understanding of Brainstem GliomasJournal of Clinical Oncology, 2006